Arteriocyte is now a part of Isto Biologics.

News + Views


ISTO Technologies to Present at 12th Annual 2014 Musculoskeletal New Ventures Conference

Oct 21, 2014

October 21, 2014 (St. Louis, MO) – ISTO Technologies, Inc., a privately held regenerative medicine company, announced that Scott Gill, the Company’s Chief Financial Officer, will present at the 12th Annual 2014 Musculoskeletal New Ventures Conference, as follows:

Event: 12th Annual 2014 Musculoskeletal New Ventures Conference
Date: October 28, 2014
Time: 2:00 pm CDT
Location: The FedEx Institute of Technology at the University of Memphis

The event, hosted by MB Venture Partners and Memphis Bioworks Foundation, is a two-day conference aimed at bringing together senior executives and top decision-makers in the musculoskeletal industry.

Investors and media wishing to attend or learn more about the event should visit

About ISTO Technologies, Inc.
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. The Company’s proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue. In addition to cell-based cartilage products in clinical development, ISTO manufactures and markets InQu®, a bone graft extender and substitute for spinal fusion applications that has been used in over 30,000 surgeries at U.S. hospitals to date. For additional information on ISTO, please visit our website at

To top